Article Text

other Versions

Download PDFPDF
Original research
MT-DRAGON score for outcome prediction in acute ischemic stroke treated by mechanical thrombectomy within 8 hours
  1. Wagih Ben Hassen1,
  2. Nicolas Raynaud2,
  3. Nicolas Bricout3,
  4. Gregoire Boulouis4,
  5. Laurence Legrand5,
  6. Marc Ferrigno6,7,
  7. Apolline Kazemi8,
  8. Martin Bretzner3,
  9. Sebastien Soize9,
  10. Wassim Farhat10,
  11. Pierre Seners11,
  12. Guillaume Turc11,
  13. Mathieu Zuber12,
  14. Catherine Oppenheim1,
  15. Charlotte Cordonnier7,
  16. Olivier Naggara4,
  17. Hilde Henon13
  1. 1Neuroradiology, Centre Hospitalier Sainte Anne, Paris, France
  2. 2Radiology, Centro-hospitalo Universitaire de Poitiers, Poitiers, France
  3. 3Department of Interventional Neuroradiology, Centre Hospitalier Regional Universitaire de Lille, Lille, France
  4. 4Neuroradiology, Hospital Saint Anne, Paris, France
  5. 5Department of Neuroradiology, Centre Hospitalier Sainte Anne, Paris, France
  6. 6Inserm U1171-Degenerative and Vascular Cognitive Disorders, Lille, France
  7. 7Neurology-Stroke Unit, Univ Lille, CHU Lille, Lille, France
  8. 8Interventional Neuroradiology, Univ Lille, CHU Lille, Lille, France
  9. 9Radiology, University Hospital Reims, Reims, France
  10. 10Neurology, Centre Hospitalier Saint Joseph, Paris, France
  11. 11Department of Neurorlogy, Centre Hospitalier Sainte Anne, Paris, France
  12. 12Neurology, Groupe Hospitalier Paris Saint Joseph, Paris, Île-de-France, France
  13. 13Department of Vascular Neurology, Centre Hospitalier Regional Universitaire de Lille, Lille, France
  1. Correspondence to Pr. Olivier Naggara; o.naggara{at}ghu-paris.fr

Abstract

Objectives The MRI-DRAGON score includes clinical and MRI parameters and demonstrates a high specificity in predicting 3 month outcome in patients with acute ischemic stroke (AIS) treated with intravenous tissue plasminogen activator (IV tPA). The aim of this study was to adapt this score to mechanical thrombectomy (MT) in a large multicenter cohort.

Methods Consecutive cases of AIS treated by MT between January 2015 and December 2017 from three stroke centers were reviewed (n=1077). We derived the MT-DRAGON score by keeping all variables of the MRI-DRAGON score (age, initial National Institutes of Health Stroke Scale score, glucose level, pre-stroke modified Rankin Scale (mRS) score, diffusion weighted imaging-Alberta Stroke Program Early CT score ≤5) and considering the following variables: time to groin puncture instead of onset to IV tPA time and occlusion site. Unfavorable 3 month outcome was defined as a mRS score >2. Score performance was evaluated by c statistics and an external validation was performed.

Results Among 679 included patients (derivation and validation cohorts, n=431 and 248, respectively), an unfavorable outcome was similar between the derivation (51.5%) and validation (58.1%, P=0.7) cohorts, and was significantly associated with all MT-DRAGON parameters in the multivariable analysis. The c statistics for unfavorable outcome prediction was 0.83 (95%CI 0.79 to 0.88) in the derivation and 0.8 (95%CI 0.75 to 0.86) in the validation cohort. All patients (n=55) with an MT-DRAGONscore ≥11 had an unfavorable outcome and 60/63 (95%) patients with an MT-DRAGON score ≤2 points had a favorable outcome.

Conclusion The MT-DRAGON score is a simple tool, combining admission clinical and radiological parameters that can reliably predict 3 month outcome after MT.

  • stroke
  • thrombectomy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • ON and HH contributed equally.

  • WBH and NR contributed equally.

  • Contributors All authors drafted and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.